
Internal Reference Number: FOI_8820
Date Request Received: 05/08/2025 00:00:00
Date Request Replied To: 19/08/2025 00:00:00
This response was sent via: By Email
Request Summary: Atopic Dermatitis
Request Category: Researcher
| Question Number 1: I am analysing the treatment of dermatological conditions in the UK. Could you please answer the following questions. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib • Nemolizumab | |
| Answer To Question 1: Please see our response in the attached file. To accompany this answer to question 1 please also see the documents listed below: | |
| Question Number 2: In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department • Abrocitinib • Baricitinib • Dupilumab • Lebrikizumab • Tralokinumab • Upadacitinib • Nemolizumab *Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months. | |
| Answer To Question 2: Please see our response in the attached file. | |
| Question Number 3: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • 6 months to 5 • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 3: Please see our response in the attached file. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.